Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.54 - $23.65
Previous CloseN/A
Volume354.62K
Average Volume (3M)810.64K
Market Cap
$429.55M
Enterprise Value$204.47M
Total Cash (Recent Filing)$99.70M
Total Debt (Recent Filing)$21.86M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Apr 30, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding68,728,760
10 Day Avg. Volume770,954
30 Day Avg. Volume810,643
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.93
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$33.29Price Target Upside432.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
EyePoint Pharmaceuticals News
PremiumCompany Announcements
EyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
PremiumCompany Announcements
EyePoint Pharmaceuticals Reports 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment in both Phase 3 LUGANO and LUCIA studies for Duravyu in wet AMD is going faster than expected.
Product PotentialDuravyu is seen as a potential best-in-class product that may reduce the treatment burden in retinal diseases, addressing a significant unmet medical need in wet AMD.
ValuationThe stock is considered significantly undervalued, presenting a positive risk/reward scenario.
Bears Say
Financial PerformanceFor 4Q24, net loss was $41.4M, which was more than the estimated loss of $29.4M.
Investor ConcernsInitial press release lacked detail from the control arm, which likely left some investors concerned.
---
Ownership Overview
13.16% Insiders
19.18% Mutual Funds
0.23% Other Institutional Investors
57.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.54 and its highest was $23.64 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $429.55M.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Apr 30, 2025 which is in 38 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Mar 05, 2025. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.486 by -$0.154.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.67.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 68,728,760 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.486. Following the earnings report the stock price went up 8.224%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
---
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.29 (432.64% Upside)
$33.29 (432.64% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.31%
12-Months-Change
Fundamentals
Return on Equity
-43.42%
Trailing 12-Months
Asset Growth
17.82%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals (EYPT) is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products for the treatment of serious eye disorders. The company leverages its proprietary drug delivery technologies to create long-lasting therapies that address unmet medical needs in the field of ophthalmology. EyePoint Pharmaceuticals primarily serves the healthcare sector, targeting both patients and healthcare providers with its advanced treatments.
---
EYPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and a strong financial position, which were tempered by a decrease in revenue and increased operating expenses leading to a greater net loss. The advancements in clinical trials and robust financial backing are promising, yet the financial performance indicates some challenges.Read More>---
EYPT Stock 12 Month Forecast
Average Price Target
$33.29
▲(432.64% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
+33.66%
reiterated a buy rating 2 months ago
Copying Jennifer Kim's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +33.66% per trade.
---